These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 10438710

  • 1. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).
    Kamps WA, Bökkerink JP, Hählen K, Hermans J, Riehm H, Gadner H, Schrappe M, Slater R, van den Berg-de Ruiter E, Smets LA, de Vaan GA, Weening RS, van Weerden JF, van Wering ER, den der Does-van den Berg A.
    Blood; 1999 Aug 15; 94(4):1226-36. PubMed ID: 10438710
    [Abstract] [Full Text] [Related]

  • 2. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
    Stark B, Sharon R, Rechavi G, Attias D, Ballin A, Cividalli G, Burstein Y, Sthoeger D, Abramov A, Zaizov R.
    Cancer; 2000 Jan 01; 88(1):205-16. PubMed ID: 10618625
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
    Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D.
    Blood; 1994 Nov 01; 84(9):3122-33. PubMed ID: 7949185
    [Abstract] [Full Text] [Related]

  • 4. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).
    Kamps WA, Bökkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, van Weerden JF, Hermans J, Slater R, van den Berg E, Kroes WG, van der Does-van den Berg A.
    Leukemia; 2002 Jun 01; 16(6):1099-111. PubMed ID: 12040440
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991.
    Kamps WA, Veerman AJ, van Wering ER, van Weerden JF, Slater R, van der Does-van den Berg A.
    Leukemia; 2000 Dec 01; 14(12):2240-6. PubMed ID: 11187915
    [Abstract] [Full Text] [Related]

  • 6. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
    Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H.
    Blood; 2000 Jun 01; 95(11):3310-22. PubMed ID: 10828010
    [Abstract] [Full Text] [Related]

  • 7. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G.
    J Clin Oncol; 1995 Oct 01; 13(10):2497-502. PubMed ID: 7595699
    [Abstract] [Full Text] [Related]

  • 8. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H.
    Klin Padiatr; 1998 Oct 01; 210(4):192-9. PubMed ID: 9743952
    [Abstract] [Full Text] [Related]

  • 9. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, Bender-Götze C, Dörffel W, Dopfer R, Frey E.
    Klin Padiatr; 1994 Oct 01; 206(4):208-21. PubMed ID: 7526027
    [Abstract] [Full Text] [Related]

  • 10. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G.
    Haematologica; 1998 Sep 01; 83(9):791-9. PubMed ID: 9825576
    [Abstract] [Full Text] [Related]

  • 11. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

  • 12. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C, Hartmann R, Fengler R, Schober S, Arlt I, Loewke M, Henze G.
    Blood; 1994 Jun 15; 83(12):3468-72. PubMed ID: 8204875
    [Abstract] [Full Text] [Related]

  • 13. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A, Rondelli R, De Rossi G, Lo Nigro L, Porta F, Santoro N, Indolfi P, Basso G, Conter V, Aricò M, Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Haematologica; 2001 May 15; 86(5):478-84. PubMed ID: 11410410
    [Abstract] [Full Text] [Related]

  • 14. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
    Veerman AJ, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, Suciu S, Van Wering ER, Van der Does-Van der Berg A.
    J Clin Oncol; 1996 Mar 15; 14(3):911-8. PubMed ID: 8622039
    [Abstract] [Full Text] [Related]

  • 15. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.
    Ann Hematol; 2014 Oct 15; 93(10):1677-84. PubMed ID: 24863691
    [Abstract] [Full Text] [Related]

  • 16. Intensification of chemotherapy using block therapies as consolidation and reinduction therapies for acute lymphoblastic leukemia during childhood.
    Hara J, Park YD, Yoshioka A, Yumura-Yagi K, Koudera U, Hosoi G, Sako M, Kosaka Y, Sano K, Misu H, Mabuchi O, Aoyagi N, Yamamoto M, Tawa A, Miyata H, Tanaka H, Kikkawa M, Shimodera M, Kawa-Ha K, Osaka Childhood Leukemia Study Group.
    Int J Hematol; 2001 Aug 15; 74(2):165-72. PubMed ID: 11594517
    [Abstract] [Full Text] [Related]

  • 17. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
    Zdráhalová K, Štěrba J, Domanský J, Blažek B, Ptoszková H, Mihál V, Novák Z, Hak J, Procházková D, Černá Z, Timr P, Jabali Y, Sedláček P, Smíšek P, Zemanová Z, Jarošová M, Houdková A, Mejstříková E, Hrušák O, Zuna J, Janotová I, Trka J, Starý J.
    Cas Lek Cesk; 2015 Aug 15; 154(2):79-89. PubMed ID: 25994910
    [Abstract] [Full Text] [Related]

  • 18. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, Egurbide I, Hernández Rivas JM, Rivas C, Alcalá A, Besalduch J, Maciá J, Gardella S, Carnero M, Lite JM, Casanova F, Martinez M, Fontanillas M, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology. Programa para el Estudio y Tratamiento de las Hemopatías Malignas.
    Haematologica; 2001 Jun 15; 86(6):586-95. PubMed ID: 11418367
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R, Henze G, Bender-Götze C, Ebell W, Ehninger G, Friedrich W, Gadner H, Klingebiel T, Peters C, Riehm H.
    Blood; 1991 Nov 15; 78(10):2780-4. PubMed ID: 1824271
    [Abstract] [Full Text] [Related]

  • 20. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME.
    J Clin Oncol; 1998 Mar 15; 16(3):920-30. PubMed ID: 9508174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.